In our @JCO_ASCO piece out today, @VPplenarysesh and I argue that recent drug approvals based on metastasis-free survival (MFS) in #ProstateCancer illustrate the trade-off between speed and certainty in cancer drug approvals. Long thread to follow... ascopubs.org/doi/pdf/10.120…
Good treatments have dramatically improved life expectancy for patients with advanced #ProstateCancer. This is a good thing. But as life expectancy has increased, overall survival becomes a difficult endpoint to achieve in clinical trials, requiring lots of patients, time, & $$$